Статья
МОДУЛЯЦИЯ СЕРДЕЧНОЙ СОКРАТИМОСТИ ДЛЯ ЛЕЧЕНИЯ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ
В обзорной статье описываются современные представления о роли фосфоламбана в регуляции активности АТФ-зависимого кальциевого насоса и сокращения кардиомиоцитов, возможностях влияния на данные процессы модуляции сердечной сократимости нового метода лечения хронической сердечной недостаточности.
1. Ho K.K., Pinsky J.L., Kannel W.B., Levy D. The epidemiology of heart failure: the Framingham Study. J. Am. Coll. Cardiol. 1993; 22: 6A.
2. Cowie M.R., Mosterd A., Wood D.A., Deckers J.W., PooleWilson P.A., Sutton G.C., Grobbee D.E. The epidemiology of heart failure. Eur. Heart J. 1997; 18: 208.
3. Hoes A.W., Mosterd A., Grobbee D.E. An epidemic of heart failure. Recent evidence from Eu-rope. Eur. Heart J. 1998; 19, Suppl. L: L2.
4. Агеев Ф.Т., Даниелян M.O., Мареев В.Ю., Беленков Ю.Н. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения: исследование ЭПОХА-О-ХСН. Сердечная Недостаточность 2004; 5(1): 4-7.
5. Фомин И.В., Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Бадин Ю.В., Галявич А.С., Даниелян М.О., Камалов Г.М., Колбин A. А., Кечеджиева С.Г., Макарова В.Г., Макарова Н.В., Маленкова B. Ю., Сайфутдинов Р.И., Тарловская Е.И., Хохлов Р.А., Щербинина Е.В., Якушин С.С. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации данные ЭПОХА-ХСН. Сердечная Недостаточность. 2006; 7(3): 112-115.
6. Thom T., Haase N., Rosamond W., Howard V.J., Rumsfeld J., Manolio T., Zheng Z.J., Flegal K., O’Donnell C., Kittner S., Lloyd-Jones D., Goff D.C. Jr., Hong Y., Adams R., Friday G., Fu-rie K., Gorelick P., Kissela B., Marler J., Meigs J., Roger V., Sidney S., Sorlie P., Steinberger J., Wasserthiel-Smoller S., Wilson M., Wolf P. Heart Disease and Stroke Statistics 2006 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Sub-committee. Circulation. 2006; 113: e85-el51.
7. K0ber L., Torp-Pedersen C., Carlsen J.E., Bagger H., Eliasen P., Lyngborg K., Videbaek J., Cole D.S., Auclert L., Pauly N.C. A clinicaltrial of the angiotensin-converting-enzyme inhibitor tran-dolapril in patients with left ventricular dysfunction after myocardial infarction. TRACE Study Group. N. Engl. J. Med. 1995; 333: 1670-1676.
8. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357(9266): 1385-1390.
9. Julian D.G., Camm A.J., Frangin G., Janse M.J., Munoz A., Schwartz P.J., Simon P. Random-ised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investi-gators. Lancet. 1997; 349(9053): 667-674.
10. Moss A.J., Hall W.J., Cannom D.S., Daubert J.P., Higgins S.L., Klein H., Levine J.H., Saksena S., Waldo A.L., Wilber D., Brown M.W., Heo M. Improved survival with an implanted defibril-lator in patients with coronary disease at high risk for ventricular arrhythmia. N. Engl. J. Med. 1996; 335(26): 1933-1940.
11. Buxton A.E., Lee K.L., Fisher J.D., Josephson M.E., Prystowsky E.N., Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N. Engl. J. Med. 1999; 341(25): 1882-1890.
12. Moss A.J., Zareba W., Hall W.J., Klein H., Wilber D.J., Cannom D.S., Daubert J.P., Higgins S.L., Brown M.W., Andrews M.L.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Eng. J. Med. 2002; 346(12): 877-883.
13. NHLBI. Morbidity and Mortality: 2000 Chartbook on Cardiovascular, Lung, and Blood Diseas-es. Geneva: World Health Organization; 1996. 103 p.
14. Cleland J.G., Swedberg K., Follath F., Komajda M., CohenSolal A., Aguilar J.C., Dietz R., Gavazzi A., Hobbs R., Korewicki J., Madeira H.C., Moiseyev V.S., Preda I., van Gilst W.H., Widimsky J., Freemantle N., Eastaugh J., Mason J.; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur. Heart J. 2003; 24(5): 442463.
15. Cleland J.G., Daubert J.C., Erdmann E., Freemantle N., Gras D., Kappenberger L., Tavazzi L. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure. Eur. Heart J. 2006; 27(16): 1928-1932.
16. Brenyo A., Rao M., Barsheshet A., Cannom D., Ouesada A., McNitt S., Huang D.T., Moss A.J., Zareba W. ORS axis and the benefit of cardiac resynchronization therapy in patients with mildly symptomatic heart failure enrolled in MADIT-CRT. Cardiovasc. Electrophysiol. 2013; 24(4): 442-448. doi: 10.1111/jce.12057
17. Al-Ghamdi B., Shafquat A., Mallawi Y. Cardiac Contractility Modulation Device and Subcuta-neous Implantable Cardioverter Defibrillator Combination: A New Hope for Heart Failure Pa-tients with Low Ejection Fraction and Narrow ORS Complex. J. Cardiovasc. Med. Cardiol. 2016; 3(1): 018-022. doi: 10.17352/2455-2976.000024
18. Мареев Ю.В. Модуляция сердечной сократимости в лечении пациентов с хронической сердечной недостаточностью // Патология кровообращения и кардиохирургия. 2014; 18(4): 158163.
19. Sinha S.K., Calkins H.G. Cardiac contractility modulation: A new technologically advanced placebo? Heart Rhythm. 2006; 3(10): 1148-1149.
20. Bers D.M. Macromolecular complexes regulating cardiac ryanodine receptor function. J. Mol. Cell Cardiol. 2004; 37(2): 417429.
21. Mittmann C., Eschenhagen T., Scholz H. Cellular and molecular aspects of contractile dysfunc-tion in heart failure. Cardiovasc. Res. 1998; 39(2): 267-275.
22. Periasamy M., Huke S. SERCA pump level is a critical determinant of Ca(2+)homeostasis and cardiac contractility. J. Mol. Cell Cardiol. 2001; 33(6): 1053-1063.
23. Luo W., Grupp I.L., Harrer J., Ponniah S., Grupp G., Duffy J.J., Doetschman T., Kranias E.G. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ. Res. 1994; 75(3): 401-409.
24. Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure. Cardiovasc. Rem. 1998; 37(2): 279-289.
25. Hasenfuss G., Schillinger W., Lehnart S.E., Preuss M., Pieske B., Maier L.S., Prestle J., Minami K., Just H. Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation. 1999; 99(5): 641-648.
26. Butter C., Wellnhofer E., Schlegl M., Winbeck G., Fleck E., Sabbah H.N. Enhanced inotropic state of the failing left ventricle by cardiac contractility modulation electrical signals is not associatedwith increased myocardial oxygen consumption. J. Card. Fail. 2007; 13(2): 137-142.
27. Nelson G.S., Berger R.D., Fetics B.J., Talbot M., Spinelli J.C., Hare J.M., Kass D.A. Left ven-tricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation. 2000; 102(25): 3053-3059.
28. Yu C.M., Chan J.Y., Zhang O., Yip G.W., Lam Y.Y., Chan A. , Burkhoff D., Lee P.W., Fung J.W.. Impact of cardiac contractility modulation on left ventricular global and regional function and remodeling. JACC Cardiovasc. Imaging. 2009; 2(12): 1341-1349. doi: 10.1016/j.jcmg.2009.07.011
29. Lyon A.R., Samara M.A., Feldman D.S. Cardiac contractility modulation therapy in advanced systolic heart failure. Nat. Rev. Cardiol. 2013; 10(10): 584-598. doi: 10.1038/nrcardio.2013.114
30. Morita H., Suzuki G., Haddad W., Mika Y., Tanhehco E.J., Sharov V.G., Goldstein S., Ben-Haim S., Sabbah H.N. Cardiac contractility modulation with nonexcitatory electric signals improves left ventricular function in dogs with chronic heart failure. J. Card. Fail. 2003; 9(1): 69-75.
31. Imai M., Rastogi S., Gupta R.C., Mishra S., Sharov V.G., Stanley W.C., Mika Y., Rousso B., Burkhoff D., Ben-Haim S., Sabbah H.N. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J. Am. Coll. Cardiol. 2007; 49(21): 2120-2128.
32. Dupont E., Matsushita T., Kaba R.A., Vozzi C., Coppen S.R., Khan N., Kaprielian R., Yacoub M.H., Severs N.J. Altered connexin expression in human congestive heart failure. J. Mol. Cell. Cardiol. 2001; 33(2): 359-371.
33. Pappone C., Rosanio S., Burkhoff D., Mika Y., Vicedomini G. , Augello G., Shemer I., Prutchi D., Haddad W., Aviv R., Snir Y., Kronzon I., Alfieri O., Ben-Haim S.A. Cardiac contractility modulation by electric currents applied during the refractory period in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 2002; 90(12): 1307-1313.
34. Pappone C., Vicedomini G., Salvati A., Meloni C., Haddad W., Aviv R., Mika Y., Darvish N., Kimchy Y., Shemer I., Snir Y., Pruchi D., Ben-Haim S.A., Kronzon I. Electrical modulation of cardiac contractility: clinical aspects in congestive heart failure. Heart Fail. Rev. 2001; 6(1): 55-60.
35. Lawo T., Borggrefe M., Butter C., Hindricks G., Schmidinger H. , Mika Y., Burkhoff D., Pap-pone C., Sabbah H.N. Electrical signals applied during the absolute refractory period: an investi-gational treatment for advanced heart failure in patients with normal ORS duration. J. Am. Coll. Cardiol. 2005; 46(12): 2229-2236.
36. Sabbah H.N., Haddad W., Mika Y., Nass O., Aviv R., Sharov V.G., Maltsev V., Felzen B., Undrovinas A.I., Goldstein S., Darvish N., Ben-Haim S.A. Cardiac contractility modulation with the impulse dynamics signal: studies in dogs with chronic heart failure. Heart Fail. Rev. 2001; 6(1): 45-53.
37. Pappone C., Augello G., Rosanio S., Vicedomini G., Santinelli V., Romano M., Agricola E., Maggi F., Buchmayr G., Moretti G. , Mika Y., Ben-Haim S.A., Wolzt M., Stix G., Schmidinger H. First human chronic Experience with cardiac contractility modulation by nonexcitatory elec-trical currents for treating systolic heart failure. J. Cardiovasc. Electrophysiol. 2004; 15(4): 418-427.
38. Stix G., Borggrefe M., Wolpert C., Hindricks G., Kottkamp H. , Bocker D., Wichter T., Mika Y., Ben-Haim S., Burkhoff D., Wolzt M., Schmidinger H. Chronic electrical stimulation during the absolute refractory period of the myocardium improves severe heart failure. Eur. Heart J. 2004; 25(8): P. 650-655.
39. Borggrefe M.M., Lawo T., Butter C., Schmidinger H., Lunati M., Pieske B., Misier A.R., Curnis A., Bocker D., Remppis A., Kautzner J., Stuhlinger M., Leclerq C., Taborsky M., Frigerio M., Parides M., Burkhoff D., Hindricks G. Randomized, double blind study of nonexcitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur. Heart J. 2008; 29(8): 1019-1028. doi: 10.1093/eurheartj/ehn020
40. Borggrefe M., Burkhoff D. Clinical effects of cardiac contractility modulation (CCM) as a treatment for chronic heart failure. Eur. J. Heart Fail. 2012; 14(7): 703-712. doi: 10.1093/eurjhf/hfs078
41. Kadish A., Nademanee K., Volosin K., Krueger S., Neelagaru 5., Raval N., Obel O., Weiner S., Wish M., Carson P., Ellenbogen K., Bourge R., Parides M., Chiacchierini R.P., Goldsmith R., Goldstein 5., Mika Y., Burkhoff D., Abraham W.T. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J. 2011;161(2): 329-337. e1-2. doi: 10.1016/j.ahj.2010.10.025.
42. Abraham W.T., Nademanee K., Volosin K., Krueger S., Neelagaru S., Raval N., Obel O., Weiner S., Wish M., Carson P., Ellenbogen K., Bourge R., Parides M., Chiacchierini R.P., Goldsmith R., Goldstein S., Mika Y., Burkhoff D., Kadish A.; FIX-HF-5 Investigators and Coordinators. Sub-group analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. J. Card. Fail. 2011; 17(9): 710717. doi: 10.1016/j.cardfail.2011.05.006
43. Schau T., Seifert M., Meyhofer J., Neuss M., Butter C. Longterm outcome of cardiac contractility modulation in patients with severe congestive heart failure. Europace. 2011; 13(10): 1436-1444. doi: 10.1093/europace/eur153
44. Kuschyk J., Roeger S., Schneider R., Streitner F., Stach K., Rudic B., Weifi C., Schimpf R., Papavasilliu T., Rousso B., Burkhoff D, Borggrefe M. Efficacy and survival in patients with car-diac contractility modulation: Long-term single center experience in 81 patients. Int. J. Cardiol. 2015; 183: 76-81. doi: 10.1016/j.ijcard.2014.12.178
45. Giallauria F., Vigorito C., Piepoli M.F., Stewart Coats A.J. Effects of cardiac contractility modulation by non-excitatory electrical stimulation on exercise capacity and quality of life: An indi-vidual patient’s data metaanalysis of randomized controlled trials. Int. J. Cardiol. 2014; 175(2): 352-357. doi: 10.1016/j.ijcard.2014.06.005
46. Kloppe A., Lawo T., Mijic D., Schiedat F., Muegge A., Lemke B. Long-term survival with Cardiac Contractility Modulation in patients with NYHA II or III symptoms and normal ORS duration. Int. J. Cardiol. 2016; 209: 291-295. doi: 10.1016/j.ijcard.2016.02.001
47. Liu M., Fang F., Luo X.X., Shlomo B.H., Burkhoff D., Chan J.Y., Chan C.P., Cheung L., Rousso B., Gutterman D., Yu C. M. Improvement of long-term survival by cardiac contractility modulation in heart failure patients: A case-control study. Int. J.
48. SOLVD Investigators, Yusuf S., Pitt B., Davis C.E., Hood W.B. Jr., Cohn J.N. Effect of enal-april on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 1992; 327(10): 685-691.
49. Butter C., Meyhofer J., Seifert M., Neuss M., Minden H.H. First use of cardiac contractility modulation (CCM) in a patient failing CRT therapy: Clinical and technical aspects of combined therapies. Eur. J. Heart Fail. 2007; 9(9): 955-958.